Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it

Newsletter